• Datalinx

  Participated · Seed · Jan 2026

  Datalinx develops an AI data refinery platform that is deployed directly inside a customer’s data environment to convert messy, disparate data into structured, high-quality assets. The product relies on purpose-built ontologies, context-engineered agents, and an AI-assisted workflow to automate data cleansing and enrichment. By delivering governed data products, the company enables downstream applications such as analytics, personalization, and media measurement while maintaining data quality and compliance. Customers benefit from improved data usability without sacrificing control or privacy. With its newly raised capital, Datalinx plans to scale operations and meet growing demand for AI-ready data infrastructure. Financial or user metrics were not disclosed in the press coverage, and the business is still at an early, seed-stage development phase.

• Vivere Oncotherapies

  Participated · Equity · Jan 2026

  Vivere Oncotherapies engineers cancer therapies that activate the immune system to detect and eliminate solid tumors that typically evade immune surveillance. Using a proprietary bioengineering platform created at UC Berkeley, the team designs delivery vehicles that reach tumors more efficiently and release highly selective, immune-stimulating payloads. The company’s scientific approach merges engineering, immunology, and translational expertise to crack the longstanding problem of immunologically cold tumors, which are resistant to conventional checkpoint inhibitors. With its technology, Vivere aims to bring a new generation of targeted and safer immunotherapies to patients who currently have few effective options and poor prognoses. Future plans include advancing these candidates toward clinical development and expanding the platform to additional hard-to-treat cancers. Financially, the company has secured over $10 million in new capital to fuel preclinical development and platform expansion; no other operating metrics or revenue figures were disclosed.

• Resemble AI

  Participated · Equity · Dec 2025

  Founded in 2019 by Zohaib Ahmed and Saqib Muhammad and based in Mountain View, CA, Resemble AI develops AI voice generation and real-time multimodal deepfake detection technology. Its platform offers both cloud and on-premise deployment to allow organizations to analyze voice and audio without sending sensitive data to external servers. The company positions its tools for government, defense, and regulated organizations to detect synthetic media, prevent AI-generated fraud, and ensure secure handling of voice and audio data. With the $13.0M strategic investment, Resemble plans to expand into Saudi Arabia and the wider Middle East and to deploy real-time AI verification and deepfake detection solutions in those markets. The company’s recent investors include Wa’ed Ventures, Google's AI Future Fund, Sony Innovation Fund, Javelin, and Ubiquity.

• Neurona Therapeutics

  Participated · Equity · Feb 2024

  Neurona Therapeutics is developing allogeneic, off-the-shelf regenerative neural cell therapy products intended to provide long-term targeted repair of the nervous system following a single administration. Its lead candidate, NRTX-1001, comprises GABAergic interneurons and is being evaluated in two ongoing open-label multicenter Phase 1/2 trials for drug-resistant unilateral and bilateral mesial temporal lobe epilepsy (NCT05135091 and NCT06422923). The company presented updated Phase 1/2 data showing in a five-subject lower-dose cohort a median seizure reduction of 75% at six months, with four of five subjects reporting >50% reduction and two subjects reporting durable >95% reduction at 16 and 21 months; NRTX-1001 has been well tolerated and neuropsychological testing suggests absence of neurocognitive impairment. The FDA granted NRTX-1001 Regenerative Medicine Advanced Therapy (RMAT) designation in June 2024 based on these positive clinical data. Neurona plans to expand indications to neocortical focal epilepsy and other CNS disorders. Financially, the company has received multiple grants from the California Institute for Regenerative Medicine (CIRM), with cumulative CIRM commitment of $18.5M across five grants, and completed a $120M private financing in February 2024 co-led by Viking Global Investors and Cormorant Asset Management. Neurona Therapeutics is a San Francisco–based clinical-stage biotherapeutics company focused on developing regenerative, allogeneic, off-the-shelf cell therapy candidates with single-dose curative potential. Its candidates are designed to provide long-term repair of dysfunctional neural networks across multiple neurological indications. The company's lead investigational candidate, NRTX-1001, is being evaluated in an ongoing open-label, single-arm Phase I/II clinical trial for treatment of drug-resistant mesial temporal lobe epilepsy (MTLE). NRTX-1001 also has potential application in Alzheimer’s disease and other disorders of the nervous system. Led by CEO Cory R. Nicholas, Ph.D., Neurona intends to use newly raised capital to advance its wholly-owned pipeline of off-the-shelf cell therapies. The company recently raised $120M and announced that Raymond Kelleher, M.D., Ph.D., of Cormorant will be joining its board of directors. Neurona Therapeutics develops neural cell therapies intended to provide long-term repair of dysfunctional neural networks in chronic neurological disorders. Its lead candidate, NRTX-1001, is a neuronal cell therapeutic derived from human pluripotent stem cells comprising GABA-secreting interneurons designed as a one-time administration to provide local long-term inhibition. The company is advancing wholly-owned, off-the-shelf neuronal, glial, and gene-edited cell therapy candidates across multiple indications, initially targeting temporal lobe (focal) epilepsy. Neurona plans a Phase 1/2a clinical study for NRTX-1001 planned to launch later this year. The company completed a $41.5M financing that will be used to advance the pipeline; total proceeds raised to date are $135 million. Neurona describes its platform as based on a novel neural cell lineage with single-dose curative potential. Neurona Therapeutics is a pre-clinical biotechnology company focused on the transplantation of selected neurons to treat intractable neurological diseases. The company develops regenerative cell-based therapeutics composed of unique cell compositions that can be precisely targeted and integrated into damaged neural circuits. Its approach emphasizes activity-dependent regulation once transplanted into host circuitry. Neurona was founded by neuroscientists and stem cell researchers from the University of California, San Francisco, including Arturo Alvarez-Buylla, Arnold Kriegstein, John Rubenstein and Cory Nicholas. The company is led by interim CEO Tim Kutzkey and launched with a $23.5M Series A financing. Neurona is based in South San Francisco, CA and remains in the pre-clinical stage.

• Ayar Labs

  Participated · Series C · Apr 2022

  Headquartered in San Jose, CA, Ayar Labs builds co-packaged optics that move data between chips with light instead of copper, reducing power consumption while boosting bandwidth for AI infrastructure. Its flagship TeraPHY optical engine is manufactured in concert with leading semiconductor partners and is designed to slot directly into existing accelerator and switch designs. By replacing traditional electrical I/O with optical links, the technology delivers significant performance gains and cost savings in power-constrained environments. Following its latest financing, the company plans to ramp production and testing capacity, open and staff a new office in Hsinchu, Taiwan, and deepen ecosystem partnerships to speed customer deployments. Ayar Labs’ CPO solution is already qualified for industry-standard fab, manufacturing, and packaging flows, positioning it for broad adoption. The company has raised a cumulative $870 million to date, providing substantial capital to execute its global expansion and commercialization roadmap.

No current team members are available.